CAR-T cell therapy for recurrent glioblastoma
Part of Cancer clinical trials.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 70 years old, and you have recurrent glioblastoma that’s left over after surgery or biopsy at the study center.
- You finished prior treatments (like radiation and/or temozolomide or bevacizumab or other drugs) at least 4 weeks ago, and side effects are mostly mild (no more than “grade 1,” except hair loss or a few specific issues).
- A doctor confirms you can safely have a brain fluid shunt and a reservoir device placed (an Ommaya device).
- You must be well enough to function independently (KPS score 70 or higher) and have an expected life span of at least 8 weeks.
- Blood tests must meet key targets (white blood cells, platelets, hemoglobin, and several liver/kidney measures) taken within 14 days before blood collection; oxygen level must be at least 95%.
- You cannot have certain infections or major heart/lung/liver/kidney/blood problems, and you must not have HIV; people who could become pregnant must have a negative pregnancy test and use contraception for at least 3 months after screening through the last infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
This trial tests a new type of immune cell therapy called CAR-NK cells to treat glioblastoma or high-grade glioma that has come back or gotten worse after standard treatment. The cells are engineered to recognize and attack tumor cells in the brain.
This trial tests engineered immune cells (called NK cells) that are designed to fight glioblastoma, a deadly brain cancer. The cells are injected directly into the tumor and may help patients whose cancer has come back after standard treatment.
This trial tests a special immune cell treatment (CAR-T cells) that targets two proteins found on glioblastoma cells. It is for patients whose tumor has come back or not responded to standard treatments.
This trial tests a new treatment using your own immune cells that are genetically modified to find and attack brain tumor cells. It is for people with a type of brain cancer that has come back after standard therapy.
This trial tests a new CAR-T cell treatment (SNC-109) for people with glioblastoma that has come back after initial treatment. The therapy uses your own immune cells, modified in a lab, to try to attack the tumor.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.